N-Acetyltransferase and sulfotransferase activity in human prostate: Potential for carcinogen activation

Pharmacogenetics and Genomics

Volumn 16, Issue 6, 2006, Pages 391-399

  Al Buheissi, Salah Z ^a,c   Patel, Hiten R ^a,d   Meinl, Walter ^b   Hewer, Alan ^a   Bryan, Richard L ^c   Glatt, Hansruedi ^b   Miller, Ronald A ^c   Phillips, David H ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^c WHITTINGTON HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Carcinogen activation; Human prostate; N acetyltransferase; Phase II enzymes; Sulfotransferase

Indexed keywords

2 AMINO 3 METHYLIMIDAZO[4,5 F]QUINOLINE; ACETYL COENZYME A; ACYLTRANSFERASE; ADENOSINE 3' PHOSPHATE 5' PHOSPHOSULFATE; CARCINOGEN; DNA; HETEROCYCLIC AMINE; N ACETYLTRANSFERASE 1; PHOSPHORUS 32; SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; SULFOTRANSFERASE 1A3; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARCINOGEN DNA INTERACTION; CONTROLLED STUDY; CYTOPLASM; CYTOSOL; DNA DAMAGE; ENZYME ACTIVITY; ENZYME LOCALIZATION; EPITHELIUM CELL; ESTERIFICATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROXYLATION; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADULT; ARYLAMINE N-ACETYLTRANSFERASE; CARCINOGENS; CYTOPLASM; DNA ADDUCTS; EPITHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MALE; PROSTATE; SULFOTRANSFERASES;

EID: 33744485815     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/01.fpc.0000204998.22301.09     Document Type: Article

References (56)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA: A Cancer Journal for Clinicians 2002; 52:23-47.
2. Cook LS, Goldoft M, Schwartz SM, Weiss NS. Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol 1999; 161:152-155.
3. Shibata A, Whittemore AS, Imai K, Kolonel LN, Wu AH, John EM, et al. Serum levels of prostate-specific antigen among Japanese-American and native Japanese men. J Natl Cancer Inst 1997; 89:1716-1720.
4. Delfino RJ, Sinha R, Smith C, West J, White E, Lin HJ, et al. Breast cancer, heterocyclic aromatic amines from meat and N-acetyltransferase 2 genotype. Carcinogenesis 2000; 21:607-615.
5. Felton JS, Knize MG, Wood C, Wuebbles BJ, Healy SK, Stuermer DH, et al. Isolation and characterization of new mutagens from fried ground beef. Carcinogenesis 1984; 5:95-102.
6. Felton JS. Heterocyclic-amine mutagens/carcinogens in foods. In: Cooper CS, editor. Handbook of Experimental Pharmacology. Berlin: Springer; 1990. pp. 471-502.
7. Crofts FG, Sutter TR, Strickland PT. Metabolism of 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine by human cytochrome P4501A1, P4501A2 and P4501B1. Carcinogenesis 1998; 19:1969-1973.
8. Williams JA, Stone EM, Millar BC, Gusterson BA, Grover PL, Phillips DH. Determination of the enzymes responsible for activation of the heterocyclic amine 2-amino-3-methylimidazo[4,5-f]quinoline in the human breast. Pharmacogenetics 1998; 8:519-528.
9. Davis CD, Schut HA, Snyderwine EG. Enzymatic phase II activation of the N-hydroxylamines of IQ, MeIQx and PhIP by various organs of monkeys and rats. Carcinogenesis 1993; 14:2091-2096.
10. Kaderlik KR, Minchin RF, Mulder GJ, Ilett KF, Daugaard-Jenson M, Teitel CH, et al. Metabolic activation pathway for the formation of DNA adducts of the carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in rat extrahepatic tissues. Carcinogenesis 1994; 15:1703-1709.
11. Buonarati MH, Turteltaub KW, Shen NH, Felton JS. Role of sulfation and acetylation in the activation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b] pyridine to intermediates which bind DNA. Mutat Res 1990; 245:185-190.
12. Schut HA, Snyderwine EG. DNA adducts of heterocyclic amine food mutagens: implications for mutagenesis and carcinogenesis. Carcinogenesis 1999; 20:353-368.
13. Muckel E, Frandsen H, Glatt HR. Heterologous expression of human N-acetyltransferases 1 and 2 and sulfotransferase 1A1 in Salmonella typhimurium for mutagenicity testing of heterocyclic amines. Food Chem Toxicol 2002; 40:1063-1068.
14. Glatt HR, Pabel U, Meinl W, Frederiksen H, Frandsen H, Muckel E. Bioactivation of the heterocyclic aromatic amine 2-amino-3-methyl-9H-pyrido [2,3-b]indole (MeAαC) in recombinant test systems expressing human xenobiotic-metabolizing enzymes. Carcinogenesis 2004; 25:801-807.
15. Williams JA, Martin FL, Muir GH, Hewer A, Grover PL, Phillips DH. Metabolic activation of carcinogens and expression of various cytochromes P450 in human prostate tissue. Carcinogenesis 2000; 21:1683-1689.
16. Wang CY, Debiec-Rychter M, Schut HA, Morse P, Jones RF, Archer C, et al. N-Acetyltransferase expression and DNA binding of N-hydroxyheterocyclic amines in human prostate epithelium. Carcinogenesis 1999; 20:1591-1595.
17. Adams DJ, Seilman S, Amelizad Z, Oesch F, Wolf CR. Identification of human cytochromes P-450 analogous to forms induced by phenobarbital and 3-methylcholanthrene in the rat. Biochem J 1985; 232:869-876.
18. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254.
19. Stanley LA, Coroneos E, Cuff R, Hickman D, Ward A, Sim E. Immunochemical detection of arylamine N-acetyltransferase in normal and neoplastic bladder. J Histochem Cytochem 1996; 44:1059-1067.
20. Meinl W, Meerman JH, Glatt HR. Differential activation of promutagens by alloenzymes of human sulfotransferase 1A2 expressed in Salmonella typhimurium. Pharmacogenetics 2002; 12:677-689.
21. Glatt HR. Sulphotransferases. In: Ioannides C, editor. Handbook of Enzyme Systems that Metabolise Drugs and Other Xenobiotics. Sussex: John Wiley & Sons; 2002. pp. 353-439.
22. Moreno V, Glatt H, Guino E, Fisher E, Meinl W, Navarro M, et al. Polymorphisms in sulfotransferases SULT1A1 and SULT1A2 are not related to colorectal cancer. Int J Cancer 2005; 113:683-686.
23. Hall M, She MN, Wild D, Fasshauer I, Hewer A, Phillips DH. Tissue distribution of DNA adducts in CDF1 mice fed 2-amino-3-methylimidazo[4,5-f] quinoline (IQ) and 2-amino-3,4-dimethylimidazo [4,5-f]quinoline (MeIQ). Carcinogenesis 1990; 11:1005-1011.
24. Hein DW, Grant DM, Sim E. Update on consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenetics 2000; 10:291-292.
25. Hein DW, Rustan TD, Ferguson RJ, Doll MA, Gray K. Metabolic activation of aromatic and heterocyclic N-hydroxyarylamines by wild-type and mutant recombinant human NAT1 and NAT2 acetyltransferases. Arch Toxicol 1994; 68:129-133.
26. Lewis AJ, Walle UK, King RS, Kadlubar FF, Falany CN, Walle T. Bioactivation of the cooked food mutagen N-hydroxy-2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine by estrogen sulfotransferase in cultured human mammary epithelial cells. Carcinogenesis 1998; 19:2049-2053.
27. Wild D, Feser W, Michel S, Lord HL, Josephy PD. Metabolic activation of heterocyclic aromatic amines catalyzed by human arylamine N-acetyltransferase isozymes (NAT1 and NAT2) expressed in Salmonella typhimurium. Carcinogenesis 1995; 16:643-648.
28. Frandsen H, Alexander J. N-acetyltransferase-dependent activation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine: formation of 2-amino-1-methyl-6-(5-hydroxy)phenylimidazo [4,5-b]pyridine a possible biomarker for the reactive dose of 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine. Carcinogenesis 2000; 21:1197-1203.
29. Ghoshal A, Davis CD, Schut HA, Snyderwine EG. Possible mechanisms for PhIP-DNA adduct formation in the mammary gland of female Sprague-Dawley rats. Carcinogenesis 1995; 16:2725-2731.
30. Pacifici GM, Bencini C, Rane A. Acetyltransferase in humans: development and tissue distribution. Pharmacology 1986; 32:283-291.
31. Grant DM, Lottspeich F, Meyer UA. Evidence for two closely related isozymes of arylamine N-acetyltransferase in human liver. FEBS Lett 1989; 244:203-207.
32. Coroneos E, Sim E. N-acetyltransferase in human urothelium and bladder cell lines. Biochem Soc Trans 1991; 19:129S.
33. Windmill KF, McKinnon RA, Zhu X, Gaedigk A, Grant DM, McManus ME. The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies. Mutat Res 1997; 376:153-160.
34. Smelt VA, Mardon HJ, Sim E. Placental expression of arylamine N-acetyltransferases: evidence for linkage disequilibrium between NAT1*10 and NAT2*4 alleles of the two human arylamine N-acetyltransferase loci NAT1 and NAT2. Pharmacol Toxicol 1998; 83:149-157.
35. Kloth MT, Gee RL, Messing EM, Swaminathan S. Expression of N-acetyltransferase (NAT) in cultured human uroepithelial cells. Carcinogenesis 1994; 15:2781-2787.
36. Hickman D, Pope J, Patil SD, Fakis G, Smelt V, Stanley LA, et al. Expression of arylamine N-acetyltransferase in human intestine. Gut 1998; 42:402-409.
37. Williams JA, Stone EM, Fakis G, Johnson N, Cordell JA, Meinl W, et al. N-Acetyltransferases, sulfotransferases and heterocyclic amine activation in the breast. Pharmacogenetics 2001; 11:373-388.
38. Hein DW. Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta 1988; 948:37-66.
39. Kato R, Yamazoe Y. Metabolic activation and covalent binding to nucleic acids of carcinogenic heterocyclic amines from cooked foods and amino acid pyrolysates. Jpn J Cancer Res 1987; 78:297-311.
40. Minchin RF, Reeves PT, Teitel CH, McManus ME, Mojarrabi B, Ilett KF, et al. N-and O-acetylation of aromatic and heterocyclic amine carcinogens by human monomorphic and polymorphic acetyltransferases expressed in COS-1 cells. Biochem Biophys Res Commun 1992; 185:839-844.
41. Hein DW, Doll MA, Rustan TD, Gray K, Feng Y, Ferguson RJ, et al. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 1993; 14:1633-1638.
42. Zenser TV, Lakshmi VM, Rustan TD, Doll MA, Deitz AC, Davis BB, et al. Human N-acetylation of benzidine: role of NAT1 and NAT2. Cancer Res 1996; 56:3941-3947.
43. Butcher NJ, Ilett KF, Minchin RF. Functional polymorphism of the human arylamine N-acetyltransferase type 1 gene caused by C190T and G560A mutations. Pharmacogenetics 1998; 8:67-72.
44. Bruhn C, Brockmoller J, Cascorbi I, Roots I, Borchert HH. Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1). Biochem Pharmacol 1999; 58:1759-1764.
45. Fretland AJ, Doll MA, Leff MA, Hein DW. Functional characterization of nucleotide polymorphisms in the coding region of N-acetyltransferase 1. Pharmacogenetics 2001; 11:511-520.
46. McManus ME, Burgess WM, Veronese ME, Huggett A, Quattrochi LC, Tukey RH. Metabolism of 2-acetylaminofluorene and benzo(a)pyrene and activation of food-derived heterocyclic amine mutagens by human cytochromes P-450. Cancer Res 1990; 50:3367-3376.
47. Lin DX, Lang NP, Kadlubar FF. Species differences in the biotransformation of the food-borne carcinogen 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine by hepatic microsomes and cytosols from humans, rats, and mice. Drug Metab Dispos 1995; 23:518-524.
48. Snyderwine EG, Roller PP, Adamson RH, Sato S, Thorgeirsson SS. Reaction of N-hydroxylamine and N-acetoxy derivatives of 2-amino-3-methylimidazolo[4,5-f] quinoline with DNA. Synthesis and identification of N-(deoxyguanosin-8-yl)-IQ. Carcinogenesis 1988; 9:1061-1065.
49. Wild D, Dirr A, Fasshauer I, Henschler D. Photolysis of arylazides and generation of highly electrophilic DNA-binding and mutagenic intermediates. Carcinogenesis 1989; 10:335-341.
50. Sabbioni G, Wild D. Quantitative structure-activity relationships of mutagenic aromatic and heteroaromatic azides and amines. Carcinogenesis 1992; 13:709-713.
51. Levy G. Sulfate conjugation in drug metabolism: role of inorganic sulfate. Fed Proc 1986; 45:2235-2240.
52. Falany CN. Enzymology of human cytosolic sulfotransferases. FASEB J 1997; 11:206-216.
53. Glatt H, Meinl W. Pharmacogenetics of soluble sulfotransferases (SULTs). Naunyn Schmiedebergs Arch Pharmacol 2004; 369:55-68.
54. Jones AL, Roberts RC, Coughtrie MW. The human phenolsulphotransferase polymorphism is determined by the level of expression of the enzyme protein. Biochem J 1993; 296 (Pt 2):287-290.
55. Raftogianis RB, Wood TC, Otterness DM, Van Loon JA, Weinshilboum RM. Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun 1997; 239:298-304.
56. Nowell S, Ratnasinghe DL, Ambrosone CB, Williams S, Teague-Ross T, Trimble L, et al. Association of SULT1A1 phenotype and genotype with prostate cancer risk in African-Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 2004; 13:270-276.